nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

04.10.2016 | Original Article

Preclinical in vivo and in vitro comparison of the translocator protein PET ligands [¹⁸F]PBR102 and [¹⁸F]PBR111

verfasst von: S. Eberl, A. Katsifis, M. A. Peyronneau, L. Wen, D. Henderson, C. Loc’h, I. Greguric, J. Verschuer, T. Pham, P. Lam, F. Mattner, A. Mohamed, M. J. Fulham

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the metabolic profiles of the translocator protein ligands PBR102 and PBR111 in rat and human microsomes and compare their in vivo binding and metabolite uptake in the brain of non-human primates (Papio hamadryas) using PET-CT.

Methods

In vitro metabolic profiles of PBR102 and PBR111 in rat and human liver microsomes were assessed by liquid chromatography–tandem mass spectrometry. [¹⁸F]PBR102 and [¹⁸F]PBR111 were prepared by nucleophilic substitution of their corresponding p-toluenesulfonyl precursors with [¹⁸F]fluoride. List mode PET-CT brain imaging with arterial blood sampling was performed in non-human primates. Blood plasma measurements and metabolite analysis, using solid-phase extraction, provided the metabolite profile and metabolite-corrected input functions for kinetic model fitting. Blocking and displacement PET-CT scans, using PK11195, were performed.

Results

Microsomal analyses identified the O-de-alkylated, hydroxylated and N-de-ethyl derivatives of PBR102 and PBR111 as the main metabolites. The O-de-alkylated compounds were the major metabolites in both species; human liver microsomes were less active than those from rat. Metabolic profiles in vivo in non-human primates and previously published rat experiments were consistent with the microsomal results. PET-CT studies showed that K₁ was similar for baseline and blocking studies for both radiotracers; V_T was reduced during the blocking study, suggesting low non-specific binding and lack of appreciable metabolite uptake in the brain.

Conclusions

[¹⁸F]PBR102 and [¹⁸F]PBR111 have distinct metabolic profiles in rat and non-human primates. Radiometabolites contributed to non-specific binding and confounded in vivo brain analysis of [¹⁸F]PBR102 in rodents; the impact in primates was less pronounced. Both [¹⁸F]PBR102 and [¹⁸F]PBR111 are suitable for PET imaging of TSPO in vivo. In vitro metabolite studies can be used to predict in vivo radioligand metabolism and can assist in the design and development of better radioligands.

Bauer J, Sminia T, Wouterlood FG, Dijkstra CD. Phagocytic activity of macrophages and microglial cells during the course of acute and chronic relapsing experimental autoimmune encephalomyelitis. J Neurosci Res. 1994;38:365–75. doi:10.1002/jnr.490380402.CrossRefPubMed

Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (translocator protein 18 kDa) in microglia: from pathology to imaging. Prog Neurobiol. 2006;80:308–22.CrossRefPubMedPubMedCentral

Vowinckel E, Reutens D, Becher B, Verge G, Evans A, Owens T, et al. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res. 1997;50:345–53.CrossRefPubMed

Iannaccone S, Cerami C, Alessio M, Garibotto V, Panzacchi A, Olivieri S, et al. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:47–52. doi:10.1016/j.parkreldis.2012.07.002.CrossRefPubMed

Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol. 2005;57:168–75. doi:10.1002/ana.20338.CrossRefPubMed

McGeer EG, Singh EA, McGeer PL. Peripheral-type benzodiazepine binding in Alzheimer disease. Alzheimer Dis Assoc Disord. 1988;2:331–6.CrossRefPubMed

Hammoud DA, Endres CJ, Chander AR, Guilarte TR, Wong DF, Sacktor NC, et al. Imaging glial cell activation with [C-11]-R-PK11195 in patients with aids. J Neurovirol. 2005;11:346–55.CrossRefPubMed

Messmer K, Reynolds GP. Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington’s disease. Neurosci Lett. 1998;241:53–6.CrossRefPubMed

Pappata S, Levasseur M, Gunn RN, Myers R, Crouzel C, Syrota A, et al. Thalamic microglial activation in ischemic stroke detected in vivo by PET and [C-11]PK11195. Neurology. 2000;55:1052–4.CrossRefPubMed

10.

Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18:1584–93. doi:10.1038/nn.4132.CrossRefPubMedPubMedCentral

11.

Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. 2010;9:971–88. doi:10.1038/nrd3295.CrossRefPubMed

12.

Vivash LE, O’Brien TJ. Imaging microglial activation with TSPO PET: Lighting up neurological diseases? J Nucl Med. 2015. doi:10.2967/jnumed.114.141713.CrossRefPubMed

13.

Peyronneau MA, Saba W, Goutal S, Damont A, Dolle F, Kassiou M, et al. Metabolism and quantification of [18F]DPA-714, a new TSPO positron emission tomography radioligand. Drug Metab Dispos. 2013;41:122–31. doi:10.1124/dmd.112.046342.CrossRefPubMed

14.

Katsifis A, Loc’h C, Henderson D, Bourdier T, Pham T, Greguric I, et al. A rapid solid-phase extraction method for measurement of non-metabolised peripheral benzodiazepine receptor ligands, [18F]PBR102 and [18F]PBR111, in rat and primate plasma. Nucl Med Biol. 2011;38:137–48. doi:10.1016/j.nucmedbio.2010.07.008.CrossRefPubMed

15.

Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, et al. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem. 2005;48:4153–60. doi:10.1021/jm050155n.CrossRefPubMed

16.

Fookes CJ, Pham TQ, Mattner F, Greguric I, Loc’h C, Liu X, et al. Synthesis and biological evaluation of substituted [18F]imidazo[1,2-a]pyridines and [18F]pyrazolo[1,5-a]pyrimidines for the study of the peripheral benzodiazepine receptor using positron emission tomography. J Med Chem. 2008;51:3700–12.CrossRefPubMed

17.

Van Camp N, Boisgard R, Kuhnast B, Theze B, Viel T, Gregoire MC, et al. In vivo imaging of neuroinflammation: a comparative study between [F-18]PBR111, [C-11]CLINME and [C-11]PK11195 in an acute rodent model. Eur J Nucl Med Mol Imaging. 2010;37:962–72.CrossRefPubMed

18.

Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32:1–5. doi:10.1038/jcbfm.2011.147.CrossRefPubMed

19.

Owen DR, Gunn RN, Rabiner EA, Bennacef I, Fujita M, Kreisl WC, et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med. 2011;52:24–32. doi:10.2967/jnumed.110.079459.CrossRefPubMed

20.

Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol. 2000;27:627–30.CrossRefPubMed

21.

Shetty HU, Zoghbi SS, Simeon FG, Liow JS, Brown AK, Kannan P, et al. Radiodefluorination of 3-fluoro-5-(2-(2-[18F](fluoromethyl)-thiazol-4-yl)ethynyl)benzonitrile ([18F]SP203), a radioligand for imaging brain metabotropic glutamate subtype-5 receptors with positron emission tomography, occurs by glutathionylation in rat brain. J Pharmacol Exp Ther. 2008;327:727–35. doi:10.1124/jpet.108.143347.CrossRefPubMed

22.

Yokoi T, Iida H, Itoh H, Kanno I. A new graphic plot analysis for cerebral blood flow and partition coefficient with iodine-123-iodoamphetamine and dynamic SPECT validation studies using oxygen-15-water and PET. J Nucl Med. 1993;34:498–505.PubMed

23.

Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834–40. doi:10.1097/00004647-199609000-00008.CrossRefPubMed

24.

Knust EJ, Kupfernagel C, Stocklin G. Long-chain F-18 fatty acids for the study of regional metabolism in heart and liver; odd-even effects of metabolism in mice. J Nucl Med. 1979;20:1170–5.PubMed

25.

Zoghbi SS, Shetty HU, Ichise M, Fujita M, Imaizumi M, Liow JS, et al. PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med. 2006;47:520–7.PubMed

26.

Fonnum F, Johnsen A, Hassel B. Use of fluorocitrate and fluoroacetate in the study of brain metabolism. Glia. 1997;21:106–13.CrossRefPubMed

27.

Marik J, Ogasawara A, Martin-McNulty B, Ross J, Flores JE, Gill HS, et al. PET of glial metabolism using 2-18F-fluoroacetate. J Nucl Med. 2009;50:982–90. doi:10.2967/jnumed.108.057356.CrossRefPubMed

28.

Mori T, Sun LQ, Kobayashi M, Kiyono Y, Okazawa H, Furukawa T, et al. Preparation and evaluation of ethyl [18F]fluoroacetate as a proradiotracer of [18F]fluoroacetate for the measurement of glial metabolism by PET. Nucl Med Biol. 2009;36:155–62. doi:10.1016/j.nucmedbio.2008.11.006.CrossRefPubMed

29.

Peyronneau MA, Saba W, Dolle F, Goutal S, Coulon C, Bottlaender M, et al. Difficulties in dopamine transporter radioligand PET analysis: the example of LBT-999 using [18F] and [11C] labelling: part II: metabolism studies. Nucl Med Biol. 2012;39:347–59. doi:10.1016/j.nucmedbio.2011.09.006.CrossRefPubMed

30.

Zhang MR, Maeda J, Ogawa M, Noguchi J, Ito T, Yoshida Y, et al. Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for PET imaging of peripheral benzodiazepine receptor in primate brain. J Med Chem. 2004;47:2228–35.CrossRefPubMed

31.

Wilson AA, Garcia A, Parkes J, McCormick P, Stephenson KA, Houle S, et al. Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol. 2008;35:305–14. doi:10.1016/j.nucmedbio.2007.12.009.CrossRefPubMed

32.

Briard E, Zoghbi SS, Simeon FG, Imaizumi M, Gourley JP, Shetty HU, et al. Single-step high-yield radiosynthesis and evaluation of a sensitive, F-18-labeled ligand for imaging brain peripheral benzodiazepine receptors with PET. J Med Chem. 2009;52:688–99.CrossRefPubMedPubMedCentral

33.

Katsifis A, Mattner F, Dikic B, Papazian V. Synthesis of substituted [123I]imidazo[1,2-a]pyridines as potential probes for the study of the peripheral benzodiazepine receptors using SPECT. Radiochim Acta. 2000;88:229–32.CrossRef

34.

Trapani G, Franco M, Latrofa A, Ricciardi L, Carotti A, Serra M, et al. Novel 2-phenylimidazo[1,2-a]pyridine derivatives as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity, and in vivo studies. J Med Chem. 1999;42:3934–41.CrossRefPubMed

35.

Yui J, Maeda J, Kumata K, Kawamura K, Yanamoto K, Hatori A, et al. 18F-FEAC and 18F-FEDAC: PET of the monkey brain and imaging of translocator protein (18 kDa) in the infarcted rat brain. J Nucl Med. 2010;51:1301–9. doi:10.2967/jnumed.109.072223.CrossRefPubMed

36.

Saba W, Goutal S, Kuhnast B, Dolle F, Auvity S, Fontyn Y, et al. Differential influence of propofol and isoflurane anesthesia in a non-human primate on the brain kinetics and binding of [18F]DPA-714, a positron emission tomography imaging marker of glial activation. Eur J Neurosci. 2015;42:1738–45. doi:10.1111/ejn.12946.CrossRefPubMed

37.

Imaizumi M, Briard E, Zoghbi SS, Gourley JP, Hong J, Musachio JL, et al. Kinetic evaluation in nonhuman primates of two new PET ligands for peripheral benzodiazepine receptors in brain. Synapse. 2007;61:595–605. doi:10.1002/syn.20394.CrossRefPubMed

38.

Colasanti A, Guo Q, Muhlert N, Giannetti P, Onega M, Newbould RD, et al. In vivo assessment of brain white matter inflammation in multiple sclerosis with 18F-PBR111 PET. J Nucl Med. 2014;55:1112–8. doi:10.2967/jnumed.113.135129.CrossRefPubMed

39.

Guo Q, Colasanti A, Owen DR, Onega M, Kamalakaran A, Bennacef I, et al. Quantification of the specific translocator protein signal of 18F-PBR111 in healthy humans: a genetic polymorphism effect on in vivo binding. J Nucl Med. 2013;54:1915–23. doi:10.2967/jnumed.113.121020.CrossRefPubMed

40.

Bourdier T, Henderson D, Fookes CJ, Lam P, Mattner F, Fulham M, et al. Synthesis of [11C]PBR170, a novel imidazopyridine, for imaging the translocator protein with PET. Appl Radiat Isot. 2014;90:46–52. doi:10.1016/j.apradiso.2014.03.009.CrossRefPubMed

Titel: Preclinical in vivo and in vitro comparison of the translocator protein PET ligands [18F]PBR102 and [18F]PBR111
verfasst von: S. Eberl
A. Katsifis
M. A. Peyronneau
L. Wen
D. Henderson
C. Loc’h
I. Greguric
J. Verschuer
T. Pham
P. Lam
F. Mattner
A. Mohamed
M. J. Fulham
Publikationsdatum: 04.10.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3517-z

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Critical considerations on the predictive value of end-of-treatment FDG-PET in lymphoma

The delicate balance between present and future

Adjuvant post-operative I-131 therapy in differentiated thyroid carcinoma: are the 2015 ATA guidelines an exact science or a dark art?

Texture analysis of 18F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy

Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/TC

18F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with 18F-FDG and 11C-Methionine PET